# Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome

> **NCT05482464** · NA · COMPLETED · sponsor: **Oregon State University** · enrollment: 15 (actual)

## Conditions studied

- Inflammatory Bowel Syndrome

## Interventions

- **DIETARY_SUPPLEMENT:** Casein glycomacropeptide (CGMP)

## Key facts

- **NCT ID:** NCT05482464
- **Lead sponsor:** Oregon State University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2024-09-01
- **Final completion:** 2024-09-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-04-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05482464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05482464, "Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05482464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*